LIWANLI Innovation Co Ltd (3054) - Total Liabilities
Based on the latest financial reports, LIWANLI Innovation Co Ltd (3054) has total liabilities worth NT$32.86 Million TWD (≈ $1.04 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 3054 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
LIWANLI Innovation Co Ltd - Total Liabilities Trend (2003–2024)
This chart illustrates how LIWANLI Innovation Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of LIWANLI Innovation Co Ltd.
LIWANLI Innovation Co Ltd Competitors by Total Liabilities
The table below lists competitors of LIWANLI Innovation Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GPT Healthcare Ltd
NSE:GPTHEALTH
|
India | Rs1.95 Billion |
|
HCM Acquisition Corp
NASDAQ:HCMA
|
USA | $8.73 Million |
|
Surya Toto Indonesia Tbk
JK:TOTO
|
Indonesia | Rp845.61 Billion |
|
CVC Brasil Operadora e Agencia
SA:CVCB3
|
Brazil | R$3.82 Billion |
|
Al-Bad Massuot Yitzhak Ltd
TA:ALBA
|
Israel | ILA1.02 Billion |
|
Byggmästare Anders J Ahlström Holding AB (publ)
ST:AJA-B
|
Sweden | Skr6.45 Million |
|
Nerdy Inc
NYSE:NRDY
|
USA | $38.64 Million |
|
Baiksan
KO:035150
|
Korea | ₩193.10 Billion |
Liability Composition Analysis (2003–2024)
This chart breaks down LIWANLI Innovation Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See LIWANLI Innovation Co Ltd balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LIWANLI Innovation Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LIWANLI Innovation Co Ltd (2003–2024)
The table below shows the annual total liabilities of LIWANLI Innovation Co Ltd from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$39.23 Million ≈ $1.24 Million |
-22.56% |
| 2023-12-31 | NT$50.66 Million ≈ $1.60 Million |
+24.88% |
| 2022-12-31 | NT$40.57 Million ≈ $1.28 Million |
-19.47% |
| 2021-12-31 | NT$50.38 Million ≈ $1.59 Million |
-25.17% |
| 2020-12-31 | NT$67.32 Million ≈ $2.12 Million |
-59.98% |
| 2019-12-31 | NT$168.21 Million ≈ $5.30 Million |
+354.53% |
| 2018-12-31 | NT$37.01 Million ≈ $1.17 Million |
-48.10% |
| 2017-12-31 | NT$71.31 Million ≈ $2.25 Million |
-67.98% |
| 2016-12-31 | NT$222.74 Million ≈ $7.02 Million |
-60.81% |
| 2015-12-31 | NT$568.28 Million ≈ $17.90 Million |
-16.17% |
| 2014-12-31 | NT$677.92 Million ≈ $21.36 Million |
-11.24% |
| 2013-12-31 | NT$763.76 Million ≈ $24.06 Million |
+4.76% |
| 2012-12-31 | NT$729.07 Million ≈ $22.97 Million |
+67.30% |
| 2011-12-31 | NT$435.79 Million ≈ $13.73 Million |
+229.39% |
| 2010-12-31 | NT$132.30 Million ≈ $4.17 Million |
+18.58% |
| 2009-12-31 | NT$111.57 Million ≈ $3.52 Million |
-2.54% |
| 2008-12-31 | NT$114.48 Million ≈ $3.61 Million |
+44.21% |
| 2007-12-31 | NT$79.39 Million ≈ $2.50 Million |
+40.38% |
| 2006-12-31 | NT$56.55 Million ≈ $1.78 Million |
-19.64% |
| 2005-12-31 | NT$70.37 Million ≈ $2.22 Million |
-87.90% |
| 2004-12-31 | NT$581.48 Million ≈ $18.32 Million |
-20.39% |
| 2003-12-31 | NT$730.38 Million ≈ $23.01 Million |
-- |
About LIWANLI Innovation Co Ltd
LIWANLI Innovation Co., Ltd. operates in the biomedical science industry in Taiwan and internationally. The company offers Vigoway and powder collection products for male, female, elderly, and children. Its products include anti-aging desire, pro-active nutrients capsules, black elderberry powder, probiotic enzymes, oral care tablets, resveratrol red grape extract, algae DHA soft gels, shea butte… Read more